Navigation Links
Study shows Hodgkin lymphoma survivors lack post-treatment screening for other cancers
Date:6/10/2010

A population-based study of 2,071 Hodgkin lymphoma (HL) survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

The study, available online ahead of print publication in the July issue of the American Cancer Society journal Cancer (www.interscience.wiley.com DOI 10.1002/cncr.25053), followed the survivors for up to 15 years after their HL diagnosis by evaluating physician visits, imaging studies, and the use of routine and HL-specific cancer screening tests.

Survivors had CT scans at a rate three times greater than in the general population, even 10 to 15 years after their original diagnosis. "It is not clear why the CT scans were ordered, but they certainly did not appear to be an efficient way to detect relapse, particularly this long after treatment was finished," says principal investigator David Hodgson, a radiation oncologist at the Princess Margaret Hospital Cancer Program, University Health Network, and investigator at the Institute of Clinical Evaluative Sciences.

Most HL patients never experience a relapse. For those who do, they usually know something is wrong before their doctor does. It is uncommon to detect relapse with CT alone in a patient who is feeling well.

"For these patients, the telephone, not the CT scanner, is the most important technology," says Dr. Hodgson. "Oncologists need to advise their patients what symptoms should prompt them to seek medical attention and physicians have to be able to evaluate them in a timely way to decide if imaging is needed."

Despite frequent contact with both specialists and primary care providers, many survivors did not receive recommended cancer screening tests. Among those who met criteria for routine screening, 62.5% were not screened for colorectal cancer, 32.3% were not screened for breast cancer and 19.9% were not screened for cervical cancer (Pap test).

"Our results indicate that the optimal follow-up care did not happen, even though most patients had visits with both a primary care provider and an oncologist in years two through five. So there are opportunities to improve post-treatment surveillance for relapse and late effects."

Of particular concern is the finding that 87.1% of young women potentially at high risk of breast cancer because of prior radiation therapy were not screened. In the past decade, clinical practice guidelines have recommended that some patients start breast cancer screening before the usual starting age.

Says Dr. Hodgson: "Most HL patients are cured, but they can be at risk many years later of developing secondary cancers or other late effects of their initial treatment. This is why quality of follow-up care post-treatment is so important. And, increasingly, it is also important for other survivors as cure rates for several forms of cancer improve."


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. Genome-wide study identifies factors that may affect vitamin D levels
2. Study finds poor compliance with cirrhosis surveillance recommendations
3. Study finds beta blockers alone more effective for first variceal bleeding
4. Sleep colors your view of the world: Study suggests sleep may restore color perception
5. Video study finds risky food-safety behavior more common than thought
6. Few health reform options would have covered more people at lower cost than new law, study finds
7. Genetic markers could predict prostate cancer in younger men, U-M study finds
8. Study: Mining is a major driver of sub-Saharan Africas TB epidemic
9. U of M study: Monitoring cholesterol increases life expectancy
10. Study finds a seasonal variance in sleep-disordered breathing in young children
11. Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge ... now offering treatments for sleep apnea and TMJ at their office. TMJ, or ... , specifically the obstructive type, is increasingly being treated at dental offices with ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of ... college Bible teacher residing in North Carolina with his wife, Anna Marie. He and ... with six grandchildren. David is also the author of “Shadow and Substance.” , “Love, ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Oregon and PUNE, India , March 24, 2017 ... Research, titled, "Spine Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," ... is projected to reach $724 million by 2022, growing at a CAGR of ... ... Allied Market Research Logo ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ Million. ... , Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology: